Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

NCT01732861 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia Lymphocytic Chronic B-Cell

Interventions

DRUG: CC-292
DRUG: Lenalidomide

Sponsor

Celgene